ESTRO 2024 - Abstract Book

S1992

Clinical - Mixed sites, palliation

ESTRO 2024

changes graded RTOG/EORTC 1. Overall, 3 cases of RTOG/EORTC grade 3 were documented. These grade 3 toxicities were reported in the bladder for 1 gynecologic and 1 prostate cancer patient, and in the bowel for 1 prostate cancer patient. Substantial late toxicity was more prevalent among patients taking multiple medications (≥5 drugs), as represented in Figure 2.

Conclusion:

Conducting a comprehensive questionnaire among older patients provided a valuable means of pinpointing significant late-onset toxicities associated with their cancer treatment. Notably, a significant correlation was observed between the presence of prior surgical interventions and the specific location of the tumour. Additionally, a noteworthy trend emerged, showing that patients taking multiple medications, referred to as polymedicated patients, experienced a higher incidence of late toxicity in the context of their cancer treatment. Finally, the new technologies used in radiotherapy (more precise and accurate) could lead to fewer late effects, improving the quality of life of cancer patients.

Keywords: geriatric oncology; radiotherapy; late toxicity

References:

Cox, J. D., Stetz, J., & Pajak, T. F. (1995). Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). International Journal of Radiation Oncology, Biology, Physics, 31(5), 1341-1346. https://doi.org/10.1016/0360-3016(95)00060-C.

2748

Poster Discussion

Severe lymphopenia correlates with decreased OS in patients treated with SBRT and immunotherapy

Elaine Limkin 1,2 , Antonin Levy 1,2 , Vjona Cifliku 2 , François De Kermenguy 2 , Daphné Morel 2,1 , Lisa Bouarroudj 3 , Charlotte Robert 2 , Eric Deutsch 1,2 1 Gustave Roussy, Department of Radiation Oncology, Villejuif, France. 2 Gustave Roussy, UMR 1030 Molecular Radiotherapy and Therapeutic Innovation, Villejuif, France. 3 Gustave Roussy, Bioinformatics platform, Villejuif, France

Purpose/Objective:

Severe radiation-induced lymphopenia is observed in 14-87% of patients receiving radiation therapy and has been shown to possibly depend on the primary tumor site, the target volume, the radiotherapy schedule and the radiotherapy technique. In patients treated with radio-immunotherapy combinations, few studies have evaluated the incidence of lymphopenia and its impact on treatment outcomes. The aim of this study was to analyze the